Bank of America Securities has released a research report indicating that AKESO's (09926) cadonilimab achieved quarter-over-quarter growth against seasonal trends. In February, the sample drug sales revenue for AKESO reached 71.3 million yuan, representing a year-on-year increase of 319.6%. Within this, sales of cadonilimab amounted to 44.3 million yuan, a surge of 249.5% compared to the same period last year and a 9.6% increase from the previous quarter, achieving positive sequential growth even during the Lunar New Year holiday period. Meanwhile, ivonescimab's monthly sales reached 26.6 million yuan, showing continued sales expansion with a year-on-year growth of 517.4%. The firm maintains a "Buy" rating on AKESO with a target price of HK$162.8.